Literature DB >> 1987749

Detection of Ki-67 proliferation rate in breast cancer. Correlation with clinical and pathologic features.

S M Veronese1, M Gambacorta.   

Abstract

In situ determination of proliferative activity was performed on 203 breast cancers by use of Ki-67 monoclonal antibody and immunohistochemical methods. Tumor proliferation rate was analyzed and correlated to tumor size and nodal status. The relationship between Ki-67 proliferative activity and nuclear estrogen receptor content was also investigated on adjacent tissue sections. Ki-67 values ranged from 1 to 75%, with a median value of 10%. Premenopausal patients had greater Ki-67 values (median value, 14.1%) than postmenopausal ones (median value, 9.8%). The authors observed no correlation with lymph nodal involvement, whereas a statistically significant relationship with tumor size was found (P less than 0.01). An inverse correlation (Spearman's coefficient = -0.56; P less than 0.001) was seen between Ki-67 values and nuclear estrogen receptor content. These results, similar to those reported for other kinetic measurements, suggest that in situ detection of Ki-67 proliferation rate is a useful method for obtaining cell cycle information. Follow-up studies will be needed to assess an eventual prognostic relevance.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1987749     DOI: 10.1093/ajcp/95.1.30

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  14 in total

1.  Multicentric Breast Carcinoma: Evaluation of Clinicopathological and Immunohistochemical Characteristics.

Authors: 
Journal:  Breast Cancer       Date:  1996-12-20       Impact factor: 4.239

2.  DNA ploidy, S-phase, and Ki-67 antigen expression in the evaluation of cell content of pleural effusions.

Authors:  J Sikora; G Dworacki; J Zeromski
Journal:  Lung       Date:  1996       Impact factor: 2.584

3.  Comparison of vascularity and angiogenesis in primary invasive mammary carcinomas and in their respective axillary lymph node metastases.

Authors:  M J Edel; J M Harvey; J M Papadimitriou
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

4.  MIB-1 proliferative activity in invasive breast cancer measured by image analysis.

Authors:  P Querzoli; G Albonico; S Ferretti; R Rinaldi; E Magri; M Indelli; I Nenci
Journal:  J Clin Pathol       Date:  1996-11       Impact factor: 3.411

5.  PCNA and Ki67 expression in breast carcinoma: correlations with clinical and biological variables.

Authors:  E Leonardi; S Girlando; G Serio; F A Mauri; G Perrone; S Scampini; P Dalla Palma; M Barbareschi
Journal:  J Clin Pathol       Date:  1992-05       Impact factor: 3.411

6.  Ki-67 expression in primary breast carcinomas and their axillary lymph node metastases: clinical implications.

Authors:  Daehoon Park; Rolf Kåresen; Tove Noren; Torill Sauer
Journal:  Virchows Arch       Date:  2007-06-07       Impact factor: 4.064

7.  Tumor proliferative activity and response to first-line chemotherapy in advanced breast carcinoma.

Authors:  A Bonetti; M Zaninelli; S Rodella; A Molino; L Sperotto; Q Piubello; F Bonetti; R Nortilli; M Turazza; G L Cetto
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

8.  Cell proliferation in breast tumours: analysis of histological parameters Ki67 and PCNA expression.

Authors:  R P Sullivan; G Mortimer; I O Muircheartaigh
Journal:  Ir J Med Sci       Date:  1993-09       Impact factor: 1.568

9.  Thymidine labeling index and Ki-67 growth fraction in breast cancer: comparison and correlation with prognosis.

Authors:  M Rudas; M F Gnant; M Mittlböck; R Neumayer; A Kummer; R Jakesz; G Reiner; A Reiner
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

10.  Assessment of the new proliferation marker MIB1 in breast carcinoma using image analysis: associations with other prognostic factors and survival.

Authors:  S E Pinder; P Wencyk; D M Sibbering; J A Bell; C W Elston; R Nicholson; J F Robertson; R W Blamey; I O Ellis
Journal:  Br J Cancer       Date:  1995-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.